Log In
BCIQ
Print this Print this
 

AQW051

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionPartial agonist of the nicotinic acetylcholine receptor alpha 7 (CHRNA7) receptor
Molecular Target Nicotinic acetylcholine receptor alpha 7 (CHRNA7)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation
PartnerVanda Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$25.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/22/2014

$25.0M

0

0

Get a free BioCentury trial today